Coloplast A/S (CLPBY) Stock: Price, Forecast & Analyst Target
Coloplast A/S (CLPBY) — price $6.18 (-1.28%), as of the Oct 2, 2026 trading session; market cap $13.9B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Coloplast A/S · CLPBY · Healthcare · Medical - Instruments & Supplies
Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.18 | |
| Change on the day | -1.28% | |
| 52-week range | $5.64 – $9.70 | |
| Market capitalisation | $13.9B | |
| Price / earnings (trailing) | 33.65 | |
| Shares traded on the day | 72.5K | |
| Beta (volatility vs the S&P 500) | 0.53 | |
| Dividends per share (last 12 months) | $0.36 | |
| Dividend yield (last 12 months) | 5.82% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · in line with the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Our guidance for full year '25/'26 remains unchanged.
Anders Lonning-Skovgaard · Statement from
We expect full year organic revenue growth of 5% to 6%, EBIT growth in constant currencies before special items of around 5% and return on invested capital after tax before special items of around 15%. We continue to expect negative impact from currencies with around 2 to 3 percentage points impact on reported revenue growth and around 80 basis points negative impact on the reported EBIT margin.
Anders Lonning-Skovgaard · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Coloplast A/S (CLPBY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the CLPBY film — every key number, told as a short cinematic story
~2 min · open the film
What is Coloplast A/S (CLPBY), and what does it report?
Short answer · as of
Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Healthcare / Medical Instruments & Supplies SEC filing business address: Holtedam 1, DK-3050, G7, 00000. It employs 16,907 people and is led by Gavin Wood. In Q3 FY2026 it reported revenue of $1.12B and net income of $223M. The market values it at $13.9B.
What do the latest results show for Coloplast A/S (CLPBY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1.12B. Against analyst estimates the company has EPS beat 4 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.14B Aug 18, 2026
- Latest report · revenue estimate
- $1.11B Aug 18, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 18, 2026
- Latest report · EPS vs estimate
- In line Aug 18, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 18, 2026 | $1.14B | $1.11B | $0.1000 | $0.1000 |
| May 12, 2026 | $1.11B | $1.11B | $0.1000 | $0.0900 |
| Feb 6, 2026 | $1.11B | $1.12B | $0.1000 | $0.0900 |
| Nov 4, 2025 | $1.09B | $1.10B | $0.0700 | $0.0946 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1.12B | $223M | $0.10 (diluted) |
| Q2 FY2026 | $1.08B | -$148M | -$0.07 (diluted) |
| Q1 FY2026 | $1.05B | $207M | $0.09 (diluted) |
| Q4 FY2025 | $799M | $131M | $0.06 (diluted) |
What are the financial strengths and risks for Coloplast A/S (CLPBY)?
Short answer
The distress and quality screens read Altman Z 3.28 · Piotroski F 6. Trailing ratios: ROE 14.2% · ROA 4.5% · current ratio 1.75 · earnings yield 2.5% · free-cash-flow yield 7.2%.
What should you watch next at Coloplast A/S (CLPBY)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026. Current published price targets run low $7.38 · high $7.38 · consensus $7.38 · median $7.38 against a quoted price of $6.18 (as of Oct 2, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Our guidance for full year '25/'26 remains unchanged.
Anders Lonning-Skovgaard ·
We expect full year organic revenue growth of 5% to 6%, EBIT growth in constant currencies before special items of around 5% and return on invested capital after tax before special items of around 15%. We continue to expect negative impact from currencies with around 2 to 3 percentage points impact on reported revenue growth and around 80 basis points negative impact on the reported EBIT margin.
Anders Lonning-Skovgaard ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $7.38 – $7.38
- Consensus target
- $7.38
- Median target
- $7.38
Consensus record · Captured .
Measured against a quoted price of $6.18 (as of Oct 2, 2026).
What has been published about Coloplast A/S (CLPBY)?
CLPBY Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
How do SenSura Mio and SpeediCath differ from Coloplast’s surgical urology products?
SenSura Mio ostomy appliances and SpeediCath catheters support ongoing condition management and repeat use. Surgical urology devices are tied more closely to procedures addressing stones, prostate conditions, voiding dysfunction, erectile dysfunction and incontinence.
Why can Coloplast’s organic growth exceed its reported growth?
Management expects currency movements to reduce reported revenue growth even while the underlying business expands organically. The same pressure is expected to weigh on reported operating margin.
What is the CLPBY stock price today?
The last price recorded on this page for Coloplast A/S (CLPBY) is $6.18, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CLPBY price target?
The analyst consensus price target for Coloplast A/S (CLPBY) is $7.38 (range $7.38 to $7.38, median $7.38), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does CLPBY pay a dividend?
Yes. Coloplast A/S (CLPBY) shows a trailing 12-month dividend yield of 5.82%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (46 figures)
The 46 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Anders Lonning-Skovgaard (Aug 18, 2026): Our guidance for full year '25/'26 remains unchanged. Anders Lonning-Skovgaard (Aug 18, 2026): We expect full year organic revenue growth of 5% to 6%, EBIT growth in constant currencies before special items of around 5% and return on invested capital after tax before special items of around 15%. We continue to expect negative impact from currencies with around 2 to 3 percentage points impact on reported revenue growth and around 80 basis points negative impact on the reported EBIT margin. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Holtedam 1, DK-3050, G7, 00000 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Holtedam 1, Humlebæk, ZE, 3050, DK". |
FMP — 35 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $6.18 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:54:32.406Z. | |
px.change | Change on the day | -1.28% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $13.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T00:54:31.422Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.08 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 33.65 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 72.5K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.53 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Instruments & Supplies | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 16,907 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Gavin Wood | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q3 FY2026 | $1.12B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q3 FY2026 | $223M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-18.revenue_actual | Revenue · reported — report date 2026-08-18 | $1.14B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-18.revenue_estimated | Revenue · estimate — report date 2026-08-18 | $1.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-18.eps_actual | EPS · reported — report date 2026-08-18 | $0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-18.eps_estimated | EPS · estimate — report date 2026-08-18 | $0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_actual | Revenue · reported — report date 2026-05-12 | $1.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_estimated | Revenue · estimate — report date 2026-05-12 | $1.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_actual | EPS · reported — report date 2026-05-12 | $0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_estimated | EPS · estimate — report date 2026-05-12 | $0.0900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-06.revenue_actual | Revenue · reported — report date 2026-02-06 | $1.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-06.revenue_estimated | Revenue · estimate — report date 2026-02-06 | $1.12B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-06.eps_actual | EPS · reported — report date 2026-02-06 | $0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-06.eps_estimated | EPS · estimate — report date 2026-02-06 | $0.0900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $1.09B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $1.10B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.0700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | $0.0946 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $7.38 · high $7.38 · consensus $7.38 · median $7.38 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $7.38 – $7.38 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $7.38 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $7.38 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $5.64 – $9.70 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 3.28 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 14.2% · ROA 4.5% · current ratio 1.75 · earnings yield 2.5% · free-cash-flow yield 7.2% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.36 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 5.82% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-18.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.14B) with the recorded estimate ($1.11B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-18.eps_actual.comparison | Latest report · EPS vs estimate | In line | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1000) with the recorded estimate ($0.1000) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-18. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-18.revenue_actual,earn.history.depth.2026-08-18.revenue_estimated,earn.history.depth.2026-08-18.revenue_actual.comparison,earn.history.depth.2026-08-18.eps_actual.comparison,earn.history.depth.2026-08-18.eps_actual,earn.history.depth.2026-08-18.eps_estimated,earn.history.depth.2026-05-12.revenue_actual,earn.history.depth.2026-05-12.revenue_estimated,earn.history.depth.2026-05-12.eps_actual,earn.history.depth.2026-05-12.eps_estimated,earn.history.depth.2026-02-06.revenue_actual,earn.history.depth.2026-02-06.revenue_estimated,earn.history.depth.2026-02-06.eps_actual,earn.history.depth.2026-02-06.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Its extensive reach spans Denmark, the United States, the United Kingdom, France, and numerous other international regions. The company's activities are organized into three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Within Chronic Care, Coloplast provides advanced ostomy solutions, including the SenSura Mio, recognized for its adaptable fit and discretion, alongside other SenSura offerings and Brava brand accessories. This segment also delivers continence care products such as Conveen Active urine bags, SpeediCath catheters for diverse users, and the Peristeen transanal irrigation system. The Wound & Skin Care division features innovative dressings like the conforming Biatain Silicone and the hydrocolloid Comfeel. Additionally, it offers a broad spectrum of skin care items, encompassing bathing and cleansing products, moisturizers, skin protectants, antifungal treatments, hand cleansers, odor control solutions, and the specialized InterDry system for managing skin folds. Finally, the Interventional Urology segment is dedicated to crafting and commercializing surgical devices that address a range of urological and gynecological conditions, such as urinary stone disease, benign prostatic hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-18 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
Data provided for informational purposes only.